Therapeutic agents for COVID-19 are urgently needed. ACTIV-1 IM is a master protocol for a phase III clinical trial to evaluate multiple investigational immunomodulators for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is funded by the National Institutes of Health and the US program is coordinated by the Duke Clinical Research Institute.